Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 11/20 | 0.47 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3065837 | 1.00 | TYMP (0.47) | TYMPP2RY6ALDH1A1HTTP2RY14 | |
| SCHEMBL29531167 | 0.94 | TYMP (0.46) | TYMPP2RY6ALDH1A1HTTP2RY14 | |
| SCHEMBL261395 | 0.94 | TYMP (0.46) | TYMPP2RY6ALDH1A1HTTP2RY14 | |
| SCHEMBL3070612 | 0.93 | TYMP (0.54) | TYMPP2RY6ALDH1A1HTTP2RY14 | |
| SCHEMBL3070618 | 0.93 | TYMP (0.54) | TYMPP2RY6ALDH1A1HTTP2RY14 | |
| SCHEMBL3076275 | 0.92 | TYMP (0.45) | TYMPP2RY6ALDH1A1HTTP2RY14 | |
| SCHEMBL13714387 | 0.92 | TYMP (0.45) | TYMPP2RY6ALDH1A1HTTP2RY14 | |
| SCHEMBL3076277 | 0.92 | TYMP (0.45) | TYMPP2RY6ALDH1A1HTTP2RY14 | |
| SCHEMBL13204998 | 0.92 | TYMP (0.45) | TYMPP2RY6ALDH1A1HTTP2RY14 | |
| SCHEMBL21552240 | 0.92 | TYMP (0.47) | TYMPP2RY6P2RY14NT5ETMIGD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772387-B2 | Oligonucleotides comprising a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2010-08-10 | — | — | US | disclosed |
| US-7579451-B2 | Oligonucleotides comprising a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20060035254-A1 | Oligonucleotides comprising a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035254-A1 | Oligonucleotides comprising a modified or non-natural nucleobase | NT5C3B, DERA, DUT | TYMP 27/4885P2RY6 121/4885ALDH1A1 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.